Volume 6 Issue 1 January 2022 ISSN:5101195-3

## KOSOVA JOURNAL OF SURGERY

PAPERS PRESENTED AT THE FIRST CLINICAL CONGRESS OF THE KOSOVA COLLEGE OF SURGEONS SEPTEMBER 24-26, 2021





BELLAL JOSEPH: Breaking the Frailty Code: Emergency General Surgery in the Elderly

DEMETRIUS LITWIN: Hand-Assisted Laparoscopic Living Donor Hepatectomy

LIOR LEVY, ABASS SMILEY, RIFAT LATIFI: Independent Predictors of In-Hospital Mortality in Patients Undergoing Emergency Admission for Arterial Embolism and Thrombosis in the USA: A 10-Year National Dataset

LIOR LEVY, ABBAS SMILEY, RIFAT LATIFI: Mortality in Emergently Admitted Patients with Empyema: An Analysis of 18,033 Patients





# Mortality in Emergently Admitted Patients with Empyema: An Analysis of 18,033 Adult Patients

Lior Levy, BA,<sup>1</sup> Abbas Smiley, MD, MSc, PhD,<sup>2</sup> Rifat Latifi, MD, FACS, FKCS, FICS\*<sup>3</sup>

- 1. Medical Student, New York Medical College, Valhalla, NY.
- 2. Assistant Professor, Department of Surgery, Westchester Medical Center Health and New York Medical College, School of Medicine, Valhalla, New York
- 3. Department of Surgery, Westchester Medical Center Health, Valhalla, NY 10595, USA.

#### \*The Corresponding author:

RIFAT LATIFI, MD, FACS, FICS, FKCS

Minister of Health of Kosova, Department of Surgery, Westchester Medical Center Health, Taylor Pavilion, Suite D334, 100 Woods Road, Valhalla, NY 10595, USA.

e-mail: Rifat.Latifi@wmchealth.org

Funding: None. Disclosure: None

#### **Abstract**

**Introduction:** Empyema is associated with significant morbidity and mortality, if not treated properly. The aim of this study is to assess the prevalence and risk factors of mortality in emergency-admitted patients with the primary diagnosis of empyema (plural empyema), during the years 2005-2014.

Methods: This was a retrospective cohort study. Demographics and clinical data obtained from the National Inpatient Sample, 2005-2014, to evaluate non-elderly adult (18-64 years) and elderly (65+years) patients with the primary diagnosis of empyema (ICD-9 code 510) who underwent emergency hospital admission. Multivariable generalized additive model (GAM) and multivariable logistic regression model with backward elimination were used to identify association of predictors and in-hospital mortality.

**Results**: A total of 11,616 non-elderly adults and 6,417 elderly patients were studied. 29.4% in the non-elderly and 34.7% in the elderly adults were females. 280 (2.4%) non-elderly adults (28.9% female), and 511 (8.0%) elderly (32.7% female), died in the hospital. The mean (SD) age of the non-elderly adults was 48 (11) years and elderly 76 (8) years. The mean (SD) age at the time of death of non-elderly adults was 54 (9) years and for elderly 79 (8) years.

30% of the deceased non-elderly adult patients and 9.3% of the survived had a fistula (P<0.001), while, 17% of the deceased and 10.2% of the survived among the elderly had a fistula (P<0.001). Mean (SD) modified frailty index in survived and deceased nonelderly adult patients was 1.22 (1.09) and 1.65 (1.06), respectively (P<0.001). Mean (SD) modified frailty index in survived and deceased elderly patients was 1.97 (1.13) and 2.14 (1.15), respectively (P<0.001). 17.2% of the non-elderly adult patients were operated on and 82.8% were not, of which 2.3% and 3% died, respectively. 15.0% of the elderly patients were operated on and 85% were not, of which, 7.9% and 8.6% died, respectively. In the final regression model, time to operation, age, modified frailty index and presence of an associated fistula, were the significant risk factors for mortalities in all patients with operation. In patients who were not operated, age significantly increased the odds of mortality. In elderly patients with no operation, presence of an associated fistula significantly increased the odds of mortality.

**Conclusions:** Delay in operation, age, presence of a fistula and modified frailty index were the common risk factors of mortality in operated patients with the primary diagnosis of empyema admitted emergently. In elderly patients who did not undergo an operation and were



diagnosed with an empyema, having an associated fistula also significantly predicted higher odds of mortality.

**Keywords:** empyema, emergency general surgery, inhospital mortality, hospital length of stay.

#### Introduction

Empyema is a condition that often results from an infected parapneumonic effusion. Alternatively, it can be seen following trauma, surgery, esophageal perforation, or secondary to local spread from an adjacent subphrenic abscess or osteomyelitis. In the United States, there are approximately 32,000 cases per year. Empyema is associated with elevated morbidity and mortality. Chalmers et al., has identified seven key independent predictors that can determine patients at risk of development complicated parapneumonic effusion or empyema; low serum albumin <30 g/l, CRP >100 mg/l, platelet count  $>400 \times 10^9 \text{/l}$ , serum sodium <130 mmol/l, intravenous drug use, and chronic alcohol abuse. Additionally, Eren et al., established that prolonged duration of tube thoracostomy and length of intensive care unit stay, presence of contusion, laparotomy and retained haemothorax are independent predictors of posttraumatic empyema. When taking the proposals for empyema management guidelines issued by prolific scientific societies into consideration, it is evident that strong contradictions and interpretative limits emerge in finding the best treatment to be adopted. Interestingly, the relatively small size of existing studies has limited the ability to study rare outcomes of empyema including inhospital mortality. Therefore, the roles of comorbidity and risk factors of in-hospital stay, are poorly known as well. Insufficient emphasis has been placed on drawing a clear patient profile, on practices for management and understanding of the clinical, and demographic difference. This data is essential to the clarity required for an early initiation of treatment, and, therefore, is a determinant of successful outcome. The variation in demographic, clinical, and hospitalization characteristics of the patients, require a thorough analysis of clinical data, management implementation, and treatment outcomes. The aim of this study is to evaluate empyema prevalence, risk factors of mortality and hospitalized patient characteristics on a larger scale, spanning over a study of 10 years.

#### Methods

The Healthcare Cost and Utilization Project (HCUP) was established to provide multistate, administrative, population-based data on patients in a uniform format. The data is designed for health services research to enhance health care provision. The National Inpatient Sample (NIS), a large administrative database produced by the Agency for Healthcare Research and Quality (AHRQ), has been progressively used as a country-wide publicly data source, holding much potential and support for the assessment of care patterns and research outcomes. It allows novel approaches to investigate disease conditions, optimal care, and patient outcomes. The NIS utilizes the process of weighting when generating discharge samples from

community hospitals in the US, excluding rehabilitation centres, and long-term acute care facilities. This method of stratification makes it possible to make a national estimate of hospitalizations for certain factors. This retrospective cohort study extracted data on adult and elderly patients with empyema that had emergency general surgery (EGS) procedures. The sample extracted from the NIS-2005-2014. The ICD-9 code to identify patients with empyema were 510. The following characteristics of patients and hospitals were collected and analyzed: age, gender, race, income quartile, primary diagnosis, hospital ownership (government vs. private), health care insurance (Medicare, Medicaid, private insurance, self-paid, and no charge), invasive diagnostic status, surgical status, days to first procedure, hospital length of stay (HLOS), total charges and the associated comorbidities (Deficiency anemias, chronic pulmonary disease, coagulopathy, hypertension, liver disease, fluid and electrolyte disorders, metastatic cancer, renal failure, and weight loss). R software was used for statistical analysis and p<0.01 was set significant.

#### **Statistical Analysis**

Descriptive and analytical, statistical indicators were used to present the findings. Mean, standard deviation (SD), and confidence interval at 95% (CI) were calculated for numerical variables. The comparisons were done by  $\chi 2$ test for categorical variables, by t-test for parametric continuous variables, and Mann-Whitney U test for nonparametric continuous variables. The behavior of different variables in predicting the presence of mortality was evaluated by multivariable logistic regression analysis. Backward stepwise regression analysis was used to find the final predictors of mortality in the adjusted model. The p values less than 0.05 were considered significant. All analyses were done by SPSS software version 17 (SPSS Inc., Chicago, IL).

#### **Results** Gender Differences

Adult Group

11,616 adult patients (age 18-64) were admitted with the primary diagnosis of empyema and included in this study. This group was composed of 8,199 males (70.6%) and 3,417 females (29.4%) of a similar mean age. The mean (SD) age of the 280 patients who died during the study period of 2005-2014 was 54.03 (9.16) years old of which 199 were males (71.1%) and 81 were females (28.9%). Regardless of gender, most patients were white, of the first income quartile, funded largely by private insurance, and admitted to an urban teaching hospital (Table 1). The most pertinent comorbidities among the emergently admitted adult patients were hypertension, deficiency anemias, chronic pulmonary disease, uncomplicated diabetes, as well as fluid/electrolyte disorders. Men manifested significantly more comorbidities of alcohol abuse and liver disease while women showed more with deficiency anemias, chronic pulmonary disease, uncomplicated diabetes, metastatic cancer, obesity, and hypothyroidism. Further,



men manifested a significantly lower rate of the presence of a fistula relative to females, 9.2% vs 11.4% respectively (Table 1, p<0.001). All of the patients' characteristics and clinical data are summarized in Table 1.


#### Elderly Group

A total of 6,417 elderly adult patients (age 65+ years) were admitted with the primary diagnosis of empyema and included in the current study. Out of this, 4,193 were men (65.3%) and 2,224 were women (34.7%). The mean (SD) age of the female group was 76.67 (8.04), which was significantly higher than the mean age of the males at 75.49 (7.41) (p<0.001). Regardless of gender, most patients

were white, of income quartile 2, funded mostly by Medicare, and admitted to an urban teaching hospital. The major comorbidities among the emergently admitted elderly patients were hypertension, chronic pulmonary disease, deficiency anemias, uncomplicated diabetes, renal failure, and fluid/electrolyte disorders. Men manifested significantly more likely to suffer from comorbidities of alcohol abuse and liver disease while women suffered from comorbidities of deficiency anemias, chronic pulmonary disease, fluid/electrolyte disorders, obesity, and hypothyroidism. These patients' characteristics and clinical data are summarized in Table 1.


**Table 1.** Characteristics of emergency admitted patients with the primary diagnosis of empyema. Data was stratified according to sex categories, NIS 2005-2014.

Patients' Char	racteristics	Adul	t, N (%)		Elde	rly, N (%)	
		Male	Female	p	Male	Female	p
All Cases		8,199	3,417		4,193	2,224	
		(70.6%)	(29.4%)		(65.3%)	(34.7%)	
	White	5,084	2,220		3,018	1,627	
		(72.6%)	(76.5%)		(83.9%)	(86.2%)	
	Black	805	338		219	104	
		(11.5%)	(11.6%)		(6.1%)	(5.5%)	0.150
	Hispanic	722	209		174	78	
Race		(10.3%)	(7.2%)	-0.001	(4.8%)	(4.1%)	
	Asian/Pacific	137	44	<0.001	93	34	
	Islander	(2.0%)	(1.5%)		(2.6%)	(1.8%)	
	Native American	61	18		19	5	
		(0.9%)	(0.6%)		(0.5%)	(0.3%)	
	Other	197	74		72	40	
		(2.8%)	(2.5%)		(2.0%)	(2.1%)	
	Quartile 1	2,356	938		955	482	
		(29.5%)	(28.1%)		(23.3%)	(22.1%)	
	Quartile 2	2,144	900		1,080	586	
Income		(26.8%)	(27.0%)	0.240	(26.4%)	(26.9%)	0.670
Quartile	Quartile 3	1,959	864	0.340	1,052	553	0.670
		(24.5%)	(25.9%)		(25.7%)	(25.4%)	
	Quartile 4	1,530	636		1,010	557	
		(19.2%)	(19.1%)		(24.7%)	(25.6%)	





Patients' Characteristics	Adul	t, N (%)		Elder	ly, N (%)	
	Male	Female	p	Male	Female	p
Pulmonary	(27.10/)	(21.60/)	< 0.001	(44.0%)	(36.5%)	<0.001
Disease	(27.1%)	(31.6%)		(44.070)	(30.370)	
Coagulopathy	438	191	0.590	236	124	0.930
	(5.3%)	(5.6%)	0.390	(5.6%)	(5.6%)	0.930
Depression	688	526	<0.001	345	300	<0.001
	(8.4%)	(15.4%)	<b>~0.001</b>	(8.2%)	(13.5%)	<0.001
Diabetes,	1,402	498	0.001	914	396	~0 001
Uncomplicated	(17.1%)	(14.6%)	0.001	(21.8%)	(17.8%)	<b>&lt;0.001</b>
Diabetes, Chronic	317	114	0.170	187	78	0.070
Complications	(3.9%)	(3.3%)	0.170	(4.5%)	(3.5%)	0.070
Drug Abuse	770	272	0.014	31	13	0.400
	(9.4%)	(8.0%)	V.V14	(0.7%)	(0.6%)	0.480
Hypertension	2,983	1,178	0.051	2,454	1,336	0.230
	(36.4%)	(34.5%)		(58.5%)	(60.1%)	
Hypothyroidism	316	380	< 0.001	377	438	<0.001
	(3.9%)	(11.1%)		(9.0%)	(19.7%)	
Liver Disease	637	197	< 0.001	110	47	0.210
	(7.8%)	(5.8%)	<b>\0.001</b>	(2.6%)	(2.1%)	0.210
Lymphoma	71 (0.9%)	29	0.930	85	43	0.800
	71 (0.570)	(0.8%)	0.550	(2.0%)	(1.9%)	0.800
Fluid/Electrolyte	2,956	1,317	0.011	1,639	990	<0.001
Disorders	(36.1%)	(38.5%)	0.011	(39.1%)	(44.5%)	<b>\0.001</b>
Metastatic Cancer	309	221	<0.001	251	136	0.840
	(3.8%)	(6.5%)	<b>\0.001</b>	(6.0%)	(6.1%)	0.040
Other	486	252		342	190	
Neurological	(5.9%)	(7.4%)	0.004	(8.2%)	(8.5%)	0.590
Disorders	(3.770)	(7.470)		(0.270)	(8.570)	
Obesity	778	509	<0.001	195	167	<0.001
	(9.5%)	(14.9%)	~0.001	(4.7%)	(7.5%)	~0.001
Paralysis	147	64	0.770	97	39	0.140
	(1.8%)	(1.9%)	0.770	(2.3%)	(1.8%)	0.140
Peripheral	181	35		390	106	



	ó	*	ŭ,
1	×	N	V.
ř.	Ч	a,	
٦	Я	21	ĸ
	ĸ,	2	

Patients' Characteristics	Adult, N (%)			Elderly, N (%)		
	Male	Female	p	Male	Female	p
Time to Invasive Diagnostic	4.40	4.28	0.380	4.90	5.42	0.004
Procedure, Days	(4.65)	(4.48)	0.360	(5.33)	(5.58)	
Time to Surgical Procedure, Days	2.16	2.30	0.100	2.31	2.46	0.120
	(3.05)	(3.13)	0.100	(3.06)	(3.08)	0.130
Hospital Length of Stay, Days	12.06	12.51	0.015	13.11	12.65	0.530
	(9.20)	(9.97)	0.015	(10.80)	(9.93)	
T 4 LCL P II	94,217	95,800	0.060	95,220	94,426	0.220
Total Charges, Dollars	(104,502)	(112,281)	0.860	(101,345)	(105,689)	0.220

#### Mortality

Adult Group

97.6% of adult patients survived and 2.4% did not. The mean (SD) age of those who survived was 48.17 (11.44) years, of whom 8,285 were males (70.6%) and 3,331 were females (29.4%) with a similar mean age. The mean (SD) age of the 280 patients who died during the study period was significantly higher in comparison to the patients who survived, at 54.03 (9.16) and 48.17 (11.44) years old, respectively. 199 were males (71.1%) and 81 were females (28.9%), with a similar mean age. By comparing deceased to survived patients, significant differences can be seen in certain comorbidities. The deceased manifested with significantly higher rates of comorbidities of congestive heart failure, coagulopathy, liver disease, pulmonary circulation disorders, fluid/electrolyte disorders, metastatic cancer, solid tumor, renal failure, and weight loss. More of the deceased had a fistula compared to the survived group at 30% vs 9.3%, respectively (P<0.001). Another finding was that the hospital length of stay was significantly higher in the deceased vs. survived groups at 15.14 days vs. 3.07


days, respectively. (P<0.001). Patients' characteristics and clinical data can be found in Table 2.

#### Elderly Group

5,898 (92.0%) elderly patients lived and 511 (8.0%) died. The mean (SD) age of the deceased was significantly higher in comparison to the survived group, 78.70 (8.18) vs. 75.66 (7.56) years, respectively (P<0.001). In the survived patient group, 2,053 (34.8%) were women and 3,845 (65.2%) were men. The deceased group was composed of 167(32.7%) females and 344 (67.3%) males. When comparing deceased to survived patients, differences in co-morbidities were noticed. The deceased manifested higher rates of comorbidities such as: congestive heart failure, coagulopathy, fluid/electrolyte disorders, renal failure, and weight loss (P<0.001). Similarly, the deceased had higher rates of fistulas (17.0% vs. 10.2%, respectively) and a longer time of invasive diagnostic procedure (7.48 days vs. 4.85 days, respectively (P<0.001) relative to the survived group. Table 2 summarizes these patients' characteristics and clinical data.

**Table 2.** Characteristics of emergency admitted patients with the primary diagnosis of empyema. Data was classified according to outcome categories, NIS 2005-2014.

<b>Patients' Characteristics</b>	Adult, N (%)			Elderly, N (%)		
	Survived	Deceased	p	Survived	Deceased	p
All Cases	11,329	280		5,898	511	
	(97.6%)	(2.4%)		(92.0%)	(8.0%)	
Sex, Female	3,331	81	0.860	2,053	167	0.330
	(29.4%)	(28.9%)	0.860 (34.	(34.8%)	(32.7%)	0.550
White	7,140	156		4,267	374	
	(73.9%)	(65.3%)		(84.8%)	(84.0%)	
Black	1,104	39		301	22	





Comorbidities   Complication   Complex   Com	Patients' Chara	cteristics	Adı	ult, N (%)		E	derly, N (%	)
AIDS 85 (0.8%) 4 (1.4%) 0.170 0 (0%) 1 (0.2%) 0.080  Alcohol Abuse 1,198 32			Survived	Deceased	p	Survived	Deceased	p
AIDS		<b>Urban: Teaching</b>	6,141	176		2,915	255	
Alcohol Abuse			(54.2%)	(62.9%)		(49.4%)	(49.9%)	
Deficiency   3,844   66   4.001   (3,2%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,9%)   (3,1%)   (3,1.1%)   (3,1.1%)   (4,8%)   (3,1.1%)   (4,8%)   (3,1.1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (3,1%)   (4,8%)   (4,9		AIDS	85 (0.8%)	4 (1.4%)	0.170	0 (0%)	1 (0.2%)	0.080
Deficiency   3,844   66   (3.2%)   (3.9%)   (3.9%)   (3.2%)   (3.9%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.9%)   (3.2%)   (3.2%)   (3.9%)   (3.2%)   (3		Alcohol Abuse	1,198	32	0.650	187	20	0.260
Anemias (33.9%) (23.6%) <0.001 (37.7%) (31.1%) 0.003  Rheumatoid 322 12 0.150 (4.8%) (3.1%) 0.080  Chronic Blood 170 1 (0.4%) 0.130 (1.9%) 7 (1.4%) 0.380  Comorbidities  Congestive Heart 699 49 0.001 (21.5%) (33.7%) (33.7%) 0.001  Failure (6.2%) (17.5%) 0.830 (21.5%) (33.7%) 0.001  Chronic 3,221 78 0.830 (41.8%) (37.8%) 0.080  Disease  Coagulopathy 577 51 0.001 (5.1%) (18.2%) 0.001 (5.2%) (10.6%) (5.2%) (10.6%)  Depression 1,197 17 0.015 (10.2%) (8.0%)  Diabetes, 1,869 29 0.006 (10.2%) (8.0%)  Diabetes, Chronic 417 14 0.250 (20.7%) (18.0%)  Diabetes, Chronic 417 14 0.250 (41.9%) (5.1%) 0.260  Complications (3.7%) (5.0%) (5.0%) 0.001 (42.9%) (0.7%) (18.0%)  Hypertension 4,076 82 (36.0%) (29.3%) 0.021 (52.4%) (52.4%) 0.001			(10.6%)	(11.4%)	0.650	(3.2%)	(3.9%)	0.360
Anemias   (33.9%)   (23.6%)   (37.7%)   (31.1%)   (31.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (4.8%)   (3.1%)   (1.9		Deficiency	3,844	66	-0.001	2,225	159	0.002
Arthritis (2.8%) (4.3%) (4.8%) (3.1%) (0.080  Chronic Blood 170 Loss (1.5%) 1 (0.4%) 0.130 (1.9%) 7 (1.4%) 0.380  Compestive Heart 699 49 Failure (6.2%) (17.5%) (21.5%) (33.7%) (21.5%) (33.7%)  Chronic 3,221 78 Pulmonary (28.4%) (27.9%) 0.830 (41.8%) (37.8%)  Disease (5.1%) (18.2%) (5.2%) (10.6%)  Depression 1,197 17 (10.6%) (6.1%) (10.6%) (6.1%)  Diabetes, 1,869 29 (0.001 (10.2%) (8.0%)  Diabetes, Chronic 417 14 (0.25) (20.7%) (18.0%)  Diabetes, Chronic 417 14 (0.25) (20.7%) (18.0%)  Drug Abuse 1,033 (9.1%) (5.0%) (10.7%)  Hypertension 4,076 82 (36.0%) (29.3%) (29.3%) (52.4%) (52.4%)		Anemias	(33.9%)	(23.6%)	<0.001	(37.7%)	(31.1%)	0.003
Comorbidities		Rheumatoid	322	12	0.150	284	16	0.000
Loss		Arthritis	(2.8%)	(4.3%)	0.150	(4.8%)	(3.1%)	0.080
Comorbidities   Congestive Heart   699   49   49   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   172   40.001   1,270   173   41.8%   1,276   193   41.8%   1,278   193   41.8%   1,278   1,28%   1,28%   1,28%   1,28%   1,218   1,		Chronic Blood	170	1 (0 40/)	0.120	113	7 (1 40/)	0.290
Comorbidities Failure (6.2%) (17.5%) (21.5%) (33.7%) (30.001 Chronic Pulmonary (28.4%) (27.9%) Disease Coagulopathy 577 51 (5.1%) (18.2%)  Depression 1,197 17 (10.6%) (6.1%)  Diabetes, 1,869 29 (10.6%) Uncomplicated (16.5%) (10.4%) Diabetes, Chronic 417 14 (20.25) (20.7%) (18.0%)  Drug Abuse 1,033 (9.1%) (9.1%) Hypertension (6.2%) (17.5%) (21.5%) (21.5%) (33.7%) (21.5%) (33.7%) (33.7%) (41.8%) (37.8%) (41.8%) (37.8%) (41.8%) (37.8%) (5.2%) (10.6%) (5.2%) (10.6%) (5.2%) (10.6%) (10.2%) (8.0%) (10.2%) (8.0%) (20.7%) (18.0%) (20.7%) (18.0%) (20.7%) (18.0%) (20.7%) (20.4%) (5.1%) (20.6%) (5.1%) (21.5%) (33.7%) (41.8%) (37.8%) (41.8%) (37.8%) (41.8%) (37.8%) (41.8%) (37.8%) (5.2%) (10.6%) (5.2%) (10.6%) (5.2%) (10.6%) (5.2%) (10.6%) (5.2%) (10.6%) (5.2%) (10.6%) (5.1%) (10.2%) (5.1%) (10.2%) (10.2%) (5.1%) (10.2%) (10.2%) (5.2%) (10.6%) (5		Loss	(1.5%)	1 (0.4%)	0.130	(1.9%)	/ (1.4%)	0.380
Failure (6.2%) (17.5%) (21.5%) (33.7%)  Chronic 3,221 78 0.830 2,463 193 0.080  Disease (28.4%) (27.9%) (41.8%) (37.8%)  Coagulopathy 577 51 (5.1%) (18.2%) (5.1%) (10.6%)  Depression 1,197 17 (10.6%) (6.1%) (10.2%) (8.0%)  Diabetes, 1,869 29 0.006 (10.2%) (10.6%)  Diabetes, Chronic 417 14 (20.25) (20.7%) (18.0%)  Diabetes, Chronic 417 14 (20.25) (239) 26 (20.7%) (18.0%)  Drug Abuse 1,033 (9.1%) (5.0%) (9.1%) (9.1%) (9.1%) (10.2%) (20.3%) (50.6%) (52.4%)	Comoubidition	<b>Congestive Heart</b>	699	49	<b>-0.001</b>	1,270	172	~0.001
Pulmonary       3,221       78       0.830       2,463       193       0.080         Disease       Coagulopathy       577       51       <0.001	Comorbialities	Failure	(6.2%)	(17.5%)	<0.001	(21.5%)	(33.7%)	<0.001
Pulmonary   (28.4%)   (27.9%)   (41.8%)   (37.8%)   (0.80)		Chronic	2 221	70		2 462	102	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		Pulmonary			0.830			0.080
Complications   Complication		Disease	(28.470)	(27.9%)		(41.8%)	(37.8%)	
Depression   1,197   17   17   10.015   604   41   0.110		Coagulopathy	577	51	<b>~0.001</b>	306	54	<0.001
Diabetes,   1,869   29   1,218   92   0.160			(5.1%)	(18.2%)	<b>~0.001</b>	(5.2%)	(10.6%)	<b>~0.001</b>
Diabetes,   1,869   29   1,218   92   0.160		Depression	1,197	17	0.015	604	41	0.110
Uncomplicated       (16.5%)       (10.4%)       0.006       (20.7%)       (18.0%)       0.160         Diabetes, Chronic       417       14       239       26       0.260         Complications       (3.7%)       (5.0%)       (4.1%)       (5.1%)         Drug Abuse       1,033       8 (2.9%)       <0.001			(10.6%)	(6.1%)	0.015	(10.2%)	(8.0%)	0.110
Uncomplicated       (16.5%)       (10.4%)       (20.7%)       (18.0%)         Diabetes, Chronic       417       14       239       26         Complications       (3.7%)       (5.0%)       (4.1%)       (5.1%)         Drug Abuse       1,033       8 (2.9%)       <0.001		Diabetes,	1,869	29	0.006	1,218	92	0.160
Complications $(3.7\%)$ $(5.0\%)$ $0.250$ $(4.1\%)$ $(5.1\%)$ $0.260$ Drug Abuse $1,033$ $(9.1\%)$ $8 (2.9\%)$ $< 0.001$ $42$ $(0.7\%)$ $2 (0.4\%)$ $0.580$ Hypertension $4,076$ $(36.0\%)$ $82$ $(29.3\%)$ $0.021$ $(59.6\%)$ $3,518$ $(59.6\%)$ $268$ $(52.4\%)$		Uncomplicated	(16.5%)	(10.4%)	0.000	(20.7%)	(18.0%)	0.100
Complications $(3.7\%)$ $(5.0\%)$ $(4.1\%)$ $(5.1\%)$ Drug Abuse $1,033$ $(9.1\%)$ $8 (2.9\%)$ $< 0.001$ $42$ $(0.7\%)$ $2 (0.4\%)$ $0.580$ Hypertension $4,076$ $(36.0\%)$ $82$ $(29.3\%)$ $0.021$ $(59.6\%)$ $3,518$ $(59.6\%)$ $268$ $(52.4\%)$		Diabetes, Chronic	417	14	0.250	239	26	0.260
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Complications	(3.7%)	(5.0%)	0.230	(4.1%)	(5.1%)	0.200
(9.1%) (0.7%) <b>Hypertension</b> 4,076 82 3,518 268 (36.0%) (29.3%) (59.6%) (52.4%)  (0.7%)		Drug Abuse	1,033	8 (2.9%)	< 0.001	42	2 (0.4%)	0.580
(36.0%) (29.3%) <b>0.021</b> (59.6%) (52.4%) <b>0.001</b>			(9.1%)	0 (2.5 / 0)		(0.7%)	2 (0.170)	0.200
(36.0%) (29.3%) (59.6%) (52.4%)		Hypertension			0.021		268	0.001
Hypothyroidism 682 14 758 57								
0.480 0.270		Hypothyroidism	682	14	0.480	758	57	0.270
(6.0%) $(5.0%)$ $(12.9%)$ $(11.2%)$								
Liver Disease 781 52 142 15 0.460		Liver Disease			<0.001			0.460
(6.9%) $(18.6%)$ $(2.4%)$ $(2.9%)$			(6.9%)	(18.6%)		(2.4%)	(2.9%)	



Patients' Char	Patients' Characteristics		ılt, N (%)		E	derly, N (%	<b>6</b> )
		Survived	Deceased	p	Survived	Deceased	p
	Lymphoma	07 (0 00/)	2 (1 10/)	0.520	111	17	0.025
		97 (0.9%)	3 (1.1%)	0.520	(1.9%)	(3.3%)	0.025
	Fluid/Electrolyte	4,113	153	-0.001	2,352	273	-0.001
	Disorders	(36.3%)	(54.6%)	<0.001	(39.9%)	(53.4%)	<0.001
	Metastatic Cancer	480	49	-0.001	340	46	0.002
		(4.2%)	(17.5%)	<0.001	(5.8%)	(9.0%)	0.003
	Other	710	20		402	20	
	Neurological	710	28	0.011	492	39	0.580
	Disorders	(6.3%)	(10.0%)		(8.3%)	(7.6%)	
	Obesity	1,277	0 (2 20()	-0.001	343	19	0.040
		(11.3%)	9 (3.2%)	<0.001	(5.8%)	(3.7%)	0.049
	Paralysis	191	20	< 0.001	122	14	0.310
		(1.7%)	(7.1%)		(2.1%)	(2.7%)	
	Peripheral	204	11		447	49	
	Vascular			0.009			0.100
	Disorders	(1.8%)	(3.9%)		(7.6%)	(9.6%)	
	Psychoses	811	11	0.037	214	17	0.730
		(7.2%)	(3.9%)	0.037	(3.6%)	(3.3%)	0.730
	Pulmonary	338	21		340	35	
	Circulation	(3.0%)	(7.5%)	< 0.001	(5.8%)	(6.8%)	0.320
	Disorders	(3.070)	(7.570)		(3.670)	(0.070)	
	Renal Failure	762	32	0.002	942	145	<0.001
		(6.7%)	(11.4%)	0.002	(16.0%)	(28.4%)	<b>10.001</b>
	Solid Tumor	393	33	<0.001	486	58	0.016
		(3.5%)	(11.8%)	<b>\0.001</b>	(8.2%)	(11.4%)	0.010
	Peptic Ulcer	0 (0%)	0 (0%)		2 (0.0%)	0 (0%)	0.999
	Valvular Disease	284	11	0.140	487	55	0.051
		(2.5%)	(3.9%)	0.170	(8.3%)	(10.8%)	5.051
	Weight Loss	1,832	94	<0.001	1,380	160	<0.001
		(16.2%)	(33.6%)	-0.001	(23.4%)	(31.3%)	.0.001
	Without Fistula	10,274	196		5,299	424	
Empyema		(90.7%)	(70.0%)	<0.001	(89.8%)	(83.0%)	<0.001
ъшрусша	With Fistula	1,055	84	<0.001	599	87	<0.001
		(9.3%)	(30.0%)		(10.2%)	(17.0%)	



<b>Patients' Characteristics</b>	Ad	ult, N (%)		E	lderly, N (	<b>%</b> )
	Survived	Deceased	d p	Survived	Deceased	p
Invasive Diagnostic Procedure	3,555	80	0.320	1,670	143	0.870
	(31.4%)	(28.6%)	0.320	(28.3%)	(28.0%)	0.870
Surgical Procedure	1,942	61	0.042	877	82	0.470
	(17.1%)	(21.8%)	0.042	(14.9%)	(16.0%)	0.470
Invasive or Surgical Procedure	4,206	101	0.720	1,946	167	0.000
	(37.1%)	(36.1%)	0.720	(33.0%)	(32.7%)	0.890
	Mean	Mean		Mean	Mean	
	(SD)	(SD)	p	(SD)	(SD)	р
Age, Years	48.17	54.03	<0.001	75.66	78.70	<0.001
	(11.44)	(9.16)	<0.001	(7.56)	(8.18)	<0.001
<b>Modified Frailty Index Score</b>	1.22	1.65	<0.001	1.97	2.14	<0.001
	(1.09)	(1.06)	<0.001	(1.13)	(1.15)	<0.001
Time to Invasive Diagnostic	4.29	7.63	0.007	4.85	7.48	<0.001
Procedure, Days	(4.43)	(9.33)	0.007	(5.19)	(7.07)	<b>~0.001</b>
Time to First Surgical Procedure,	2.18	3.20	0.340	2.33	2.79	0.031
Days	(2.99)	(5.70)	0.540	(3.01)	(3.69)	0.031
Hospital Length of Stay, Days	12.07	16.57	0.030	12.74	15.40	0.600
	(9.15)	(16.79)	0.030	(9.68)	(17.29)	0.000
Total Charges, Dollars	92,277	190,996	<0.001	91,277	138,329	<0.001
Total Charges, Donars	(100,826)	(230,462)	~v.001	(95,230)	(162,229)	~0.001

### **Operation vs. No Operation**Adult Group

The stratified analysis, based on the surgical procedure status, is presented in Table 3. 2,005 (17.2%) adult patients had a surgical procedure. Most patients were males. The racial breakdown, by proportion of cases in decreasing order was White, Black, Hispanic, Asian/Pacific Islander, and Native American. Regardless of the gender, most patients were of income quartile 1 and were funded mostly by private insurance. A significantly higher rate of the surgery patient group was admitted to urban teaching hospitals, who were not operated on. In the surgical procedure group, the rate of the comorbidities of weight loss and fluid/electrolyte disorders, was significantly higher in comparison to the non-operated patients. They furthermore manifested higher rates of fistula compared to the latter group. The operated patient sample also underwent a significantly higher rate of invasive diagnostic procedure in comparison to the nonsurgical procedure group as well as a significantly longer HLOS. Patients' characteristics and clinical data are found in Table 3.

#### Elderly Group


The stratified analysis, based on the surgery status, is presented in Table 3. 960 (15.0%) elderly patients had a surgery. Most patients were males, and the racial breakdown, by proportion of cases in decreasing order was White, Black, Hispanic, Asian/Pacific Islander, and Native American. Higher proportion of the surgery procedure group were admitted to urban teaching hospitals. In the group that had a surgical procedure, the rate of comorbidity with renal failure was significantly higher in comparison to the non-surgery procedure group. They furthermore manifested higher rate of fistula, higher rate of invasive diagnostic procedure, and longer HLOS. Patients' characteristics and clinical data are summarized in Table 3.

**Table 3.** Characteristics of emergency admitted patients with the primary diagnosis of empyema. Data was stratified according to surgery status, NIS 2005-2014.

Patients' Char	acteristics		t, N (%)			rly, N (%)	
		No Surgery	Surgery	p	No Surgery	Surgery	p
All Cases		9,619	2,005		5,457	960	
		(82.8%)	(17.2%)		(85.0%)	(15.0%)	
Sex, Female		2,830	587	0.880	1,902	322	0.430
		(29.4%)	(29.3%)	0.880	(34.9%)	(33.5%)	0.430
	White	6,067	1,237		3,946	699	
		(74.0%)	(72.2%)		(84.8%)	(84.5%)	
	Black	919	224		275	48	
		(11.2%)	(13.1%)		(5.9%)	(5.8%)	
	Hispanic	791	140		213	39	
Race		(9.7%)	(8.2%)	0.014	(4.6%)	(4.7%)	0.008
Kace	Asian/Pacific	146	35	0.014	107	20	0.998
	Islander	(1.8%)	(2.0%)		(2.3%)	(2.4%)	
	Native American	61	18		21	2 (0 40/)	
		(0.7%)	(1.1%)		(0.5%)	3 (0.4%)	
	Other	212	59		94	18	
		(2.6%)	(3.4%)		(2.0%)	(2.2%)	
	Quartile 1	2,743	551		1,231	206	
Income		(29.3%)	(28.1%)	0.000	(23.0%)	(22.1%)	0.170
Quartile	Quartile 2	2,552	496	0.080	1,438	228	
		(27.2%)	(25.3%)		(26.9%)	(24.5%)	
	Quartile 3	2,316	507		1,365	240	
		(24.7%)	(25.9%)		(25.5%)	(25.8%)	
	Quartile 4	1,764	405		1,310	257	
		(18.8%)	(20.7%)		(24.5%)	(27.6%)	
	Private Insurance	3,982	916		452	83	
		(41.5%)	(45.8%)		(8.3%)	(8.7%)	
	Medicare	1,673	312		4,855	848	
		(17.5%)	(15.6%)		(89.1%)	(88.4%)	
	Medicaid	1,730	379		63	14	
		(18.0%)	(19.0%)	y 200 to 10	(1.2%)	(1.5%)	J. 22000 000
Insurance	Self-Pay	1,430	251	0.001	25		0.620
	v	(14.9%)	(12.6%)		(0.5%)	2 (0.2%)	



<b>Patients' Chara</b>	cteristics	Adul	t, N (%)		Elder	ly, N (%)	
		No Surgery	Surgery	p	No Surgery	Surgery	p
	No Charge	186	37		70 - MONTON 1910	U 000000 900	
	G	(1.9%)	(1.9%)		0 (0%)	0 (0%)	
	Other	586	105		53	12	
		(6.1%)	(5.3%)		(1.0%)	(1.3%)	
	Rural	835	105		536	54	
		(8.7%)	(5.2%)		(9.8%)	(5.6%)	
Hospital	Urban: Non-	3,609	751	0.004	2,249	404	<0.001
Location	Teaching	(37.5%)	(37.5%)	< 0.001	(41.2%)	(42.1%)	
	Urban: Teaching	5,175	1,149		2,672	502	
		(53.8%)	(57.3%)		(49.0%)	(52.3%)	
	AIDS	73	16	0.860	1 (0.0%)	0 (0%)	0.999
		(0.8%)	(0.8%)	0.800	1 (0.070)	0 (078)	0.999
	Alcohol Abuse	1,010	224	0.370	183	24	0.170
		(10.5%)	(11.2%)	0.570	(3.4%)	(2.5%)	0.170
	Deficiency	3,224	689	0.470	2,047	339	0.190
	Anemias	(33.5%)	(34.4%)	0.470	(37.5%)	(35.3%)	0.190
	Rheumatoid	268	66	0.220	251	49	0.500
	Arthritis	(2.8%)	(3.3%)	0.220	(4.6%)	(5.1%)	0.300
	Chronic Blood	134	37	0.130	103	17	0.810
	Loss	(1.4%)	(1.8%)	0.130	(1.9%)	(1.8%)	0.610
Comorbidities	<b>Congestive Heart</b>	624	127	0.800	1,253	189	0.025
Comorbidities	Failure	(6.5%)	(6.3%)	0.800	(23.0%)	(19.7%)	0.023
	Chronic	2,672	631	0.001	2,233	426	0.045
	Pulmonary Disease	e (27.8%)	(31.5%)	0.001	(40.9%)	(44.4%)	0.043
	Coagulopathy	519	110	0.870	303	57	0.630
		(5.4%)	(5.5%)	0.870	(5.6%)	(5.9%)	0.030
	Depression	1,017	197	0.320	551	94	0.770
		(10.6%)	(9.8%)	0.320	(10.1%)	(9.8%)	0.770
	Diabetes,	1,581	320	0.600	1,102	208	0.300
	Uncomplicated	(16.4%)	(16.0%)	0.000	(20.2%)	(21.7%)	0.500
	Diabetes, Chronic	365	66	0.200	232	33	0.240
	Complications	(3.8%)	(3.3%)	0.280	(4.3%)	(3.4%)	0.240



	×	-	i,
1	×	V	Z
÷.	4	ľ	
1	×	2	s
	٩,		

<b>Patients' Characteristics</b>	Adu	lt, N (%)		Elderly, N (%)			
	No Surgery	Surgery	p	No Surgery	Surgery	p	
	` /	` /		× /	` /		
Peptic Ulce	r 0 (0%)	0 (0%)		2 (0.0%)	0 (0%)	0.999	
Valvular Di	sease 243	53	0.760	472	70	0.160	
	(2.5%)	(2.6%)	0.760	(8.6%)	(7.3%)	0.160	
Weight Los	s 1,504	426	-0.001	1,305	239	0.510	
	(15.6%)	(21.2%)	<0.001	(23.9%)	(24.9%)	0.510	
Without Fis	stula 8,784	1,700		4,935	795		
F	(91.3%)	(84.8%)	م. م. ۵. ۵. ۵. ۱	(90.4%)	(82.8%)	-0.001	
Empyema With Fistul	a 835	305	<0.001	522	165	<0.001	
	(8.7%)	(15.2%)		(9.6%)	(17.2%)		
Invasive Diagnostic Procedu	2,307	1,332	.0.001	1,157	659	-0.001	
	(24.0%)	(66.4%)	<0.001	(21.2%)	(68.6%)	<0.001	

#### Fistula Status

Adult Group


Table 4 presents the stratified analysis, based on fistula status. 1,140 (9.8%) adult patients had fistula. The mean age of the fistula group was significantly higher in comparison to the non-fistula group. The fistula group had higher rate of comorbidities such as chronic pulmonary disease, metastatic cancer, solid tumor, weight loss and obesity. They furthermore manifested higher rates of invasive or surgical procedure compared to the non-fistula group as well as longer time to their first procedure, higher mortality rate and a longer HLOS. Patient characteristics and clinical data are summarized in Table 4.

#### Elderly Group

The stratified analysis, based on the fistula status, is presented in Table 4. 687 (10.7%) elderly patients had fistula. The mean age of the fistula group was significantly lower in comparison to the non-fistula group. The fistula group had higher rate of comorbidities with solid tumour and weight loss. They, furthermore, manifested a higher rate of invasive or surgical procedure compared to the other groups, and higher rate of mortality. Patients' characteristics and clinical data are summarized in Table 4.

**Table 4.** Characteristics of emergency admitted patients with the primary diagnosis of empyema. Data was stratified according to fistula status, NIS 2005-2014.

Patients' Characteristics		Adult	Adult, N (%)			Elderly, N (%)		
		No Fistula	Fistula	p	No Fistula	Fistula	p	
All Cases		10,484	1,140		5,730	687		
		(90.2%)	(9.8%)		(89.3%)	(10.7%)		
Sex, Femal	le	3,029	388	-0 001	2,015	209	0.014	
		(28.9%)	(34.1%)	< <b>0.001</b>	(35.2%)	(30.4%)	0.014	
	White	6,619	685		4,146	499		
		(74.0%)	(71.1%)		(84.9%)	(83.6%)		
Race	Black	1,007	136	0.110	283	40	0.020	
		(11.3%)	(14.1%)		(6.7%)	0.930		
	Hispanic	841	90		224	28		
		(9.4%)	(9.3%)		(4.6%)	(4.7%)		





Patients' Characteristics		Adult, N (%)			Elderly, N (%)		
		No Fistula	Fistula	p	No Fistula	Fistula	p
	AIDS	74	15	0.025	1 (0 00/)	0 (00/)	0.000
		(0.7%)	(1.3%)	0.025	1 (0.0%)	0 (0%)	0.999
	Alcohol Abuse	1,133	101	0.043	188	19	0.470
		(10.8%)	(8.9%)		(3.3%)	(2.8%)	0.470
	Deficiency	3,547	366	0.40	2,177	209	0.004
	Anemias	(33.8%)	(32.1%)	0.240	(38.0%)	(30.4%)	<0.001
Comorbidities	Rheumatoid	275	59		276	24	0.120
	Arthritis	(2.6%)	(5.2%)	< 0.001	(4.8%)	(3.5%)	0.120
	Chronic Blood	152	19	0.560	114	6 (0 00/)	0.044
	Loss	(1.4%)	(1.7%)	0.560	(2.0%)	6 (0.9%)	0.041
	Congestive Heart	692	59	0.000	1,345	97	.0.004
	Failure	(6.6%)	(5.2%)	0.060	(23.5%)	(14.1%)	<0.001
	Chronic	2,825	478	<0.001	2,275	384	< 0.001
	<b>Pulmonary Disease</b>	(26.9%)	(41.9%)	40.001	(39.7%)	(55.9%)	10.001
	Coagulopathy	565	64	0.750	326	34	0.430
		(5.4%)	(5.6%)	01,70	(5.7%)	(4.9%)	01.150
	Depression	1,100	114	0.610	590	55	0.060
		(10.5%)	(10.0%)		(10.3%)	(8.0%)	
	Diabetes,	1,743	158	0.016	1,183	127	0.190
	Uncomplicated	(16.6%)	(13.9%)		(20.6%)	(18.5%)	
	Diabetes, Chronic	406	25	0.004	245	20	0.090
	Complications	(3.9%)	(2.2%)		(4.3%)	(2.9%)	
	<b>Drug Abuse</b>	969	73	0.001	36	8 (1.2%)	0.110
		(9.2%)	(6.4%)		(0.6%)		
	Hypertension	3,801	360	0.002	3,429	361	<0.001
		(36.3%)	(31.6%)		(59.8%)	(52.5%)	
	Hypothyroidism	620	76	0.310	756	59	0.001
	Livon Discour	(5.9%)	(6.7%)		(13.2%)	(8.6%)	
	Liver Disease	757	77	0.560	138	19	0.570
	Lymphoma	(7.2%) 85	(6.8%)		(2.4%)	(2.8%)	
	Lymphoma	(0.8%)	15 (1.3%)	0.080	122 (2.1%)	6 (0.9%)	0.026
	Fluid/Electrolyte	3,855	418		2,398	231	
	Disorders	(36.8%)	(36.7%)	0.950	(41.8%)	(33.6%)	<0.001
	Districts	(50.670)	(30.770)		(41.070)	(33.070)	

Patients' Characteristics	Adu No Fistula	ılt, N (%) Fistula	р	Elde No Fistula	erly, N (%) Fistula	р
Motostatia Canaca	383	147	Р	305	82	Р
Metastatic Cancer			< 0.001			< 0.001
Others	(3.7%)	(12.9%)		(5.3%)	(11.9%)	
Other	678	60	0.110	491	41	0.040
Neurological	(6.5%)	(5.3%)	0.110	(8.6%)	(6.0%)	0.019
Disorders	1.007	60		246	1.6	
Obesity	1,227	60	< 0.001	346	16	< 0.001
	(11.7%)	(5.3%)		(6.0%)	(2.3%)	
Paralysis	195	16	0.270	127	9 (1.3%)	0.120
	(1.9%)	(1.4%)		(2.2%)	, ,	
Peripheral	186	30		447	49	
Vascular	(1.8%)	(2.6%)	0.042	(7.8%)	(7.1%)	0.540
Disorders	(1.070)	(=1070)		(7.670)	(7.1273)	
Psychoses	756	66	0.080	202	29	0.360
	(7.2%)	(5.8%)	0.000	(3.5%)	(4.2%)	0.500
Pulmonary	314	45		334	42	
Circulation	(3.0%)	(3.9%)	0.080	(5.8%)	(6.1%)	0.760
Disorders	(3.070)	(3.970)		(3.870)	(0.170)	
Renal Failure	736	59	0.019	1,024	64	<0.001
	(7.0%)	(5.2%)	0.019	(17.9%)	(9.3%)	<0.001
Solid Tumor	301	125	-0 001	402	142	<0.001
	(2.9%)	(11.0%)	<0.001	(7.0%)	(20.7%)	<0.001
Peptic Ulcer	0 (0%)	0 (0%)		2 (0.0%)	0 (0%)	0.999
Valvular Disease	271	25	0.430	509	33	<0.001
	(2.6%)	(2.2%)	0.430	(8.9%)	(4.8%)	<b>~U.UU1</b>
Weight Loss	1,605	325	<0.001	1,354	190	0.020
	(15.3%)	(28.5%)	~0.001	(23.6%)	(27.7%)	U.U <b>2</b> U
Invasive Diagnostic Procedure	3,223	416	<0.001	1,566	250	<0.001
	(30.7%)	(36.5%)	~0.001	(27.3%)	(36.4%)	~0.001
Surgical Procedure	1,700	305	<0.001	795	165	<0.001
	(16.2%)	(26.8%)	~0.001	(13.9%)	(24.0%)	~0.001
Invasive or Surgical Procedure	3,761	551	<0.001	1,801	316	<0.001
	(35.9%)	(48.3%)	<b>~0.001</b>	(31.4%)	(46.0%)	<b>~U.UU1</b>



Patients' Characteristics	Adult, N (%)		Elderly, N (%)			
	No Fistula	Fistula	p	No Fistu	la Fistula	p
Valvular Disease	271	25	0.430	509	33	<0.001
	(2.6%)	(2.2%)	0.430	(8.9%)	(4.8%)	<0.001
Weight Loss	1,605	325	<0.001	1,354	190	0.020
	(15.3%)	(28.5%)	<0.001	(23.6%)	(27.7%)	0.020
Invasive Diagnostic Procedure	3,223	416	<0.001	1,566	250	< 0.001
	(30.7%)	(36.5%)	<0.001	(27.3%)	(36.4%)	<0.001
Surgical Procedure	1,700	305	<0.001	795	165	< 0.001
	(16.2%)	(26.8%)	<b>~0.001</b>	(13.9%)	(24.0%)	<b>~0.001</b>
Invasive or Surgical Procedure	3,761	551	<0.001	1,801	316	< 0.001
	(35.9%)	(48.3%)	<b>~0.001</b>	(31.4%)	(46.0%)	<b>~0.001</b>
T. J.G. D. II	91.293	125,568	.0.004	92,972	111,615	0.220
Total Charges, Dollars	(87,753) (165,788) (165,788)		<0.001	(94,657)	(154,936)	0.220

#### Risk Factors of Mortality

The multivariable logistic regression model for mortality was built for the group with operation and, subsequently, compared with the model built for the group with no operation. The findings are presented in Tables 5 and 6. Common variables used to adjust the two models were age, sex, income, insurance, and empyema with fistula. In the final multivariable regression model for both age groups that underwent an operation, time to operation, age, modified frailty index and presence of an associated fistula were the significant risk factors for mortalities (Table 5). In all patients that were not operated, just age

significantly increased the odds of mortality (Table 6). In adults and elderly patients who underwent a surgical operation, each additional day of delay in time to operation increased the odds of mortality by 4.9% and 3.7%, respectively. The frailty index revealed 15.1% and 14.6% higher odds of mortality for each additional score increase in adults and elderly's scores, respectively, who had surgery. (Table 5). In adults and elderly who did not have a surgery, each year of older age correlated with increased odds of mortality by 3.9% and 5.4%, respectively. In the elderly group also having a fistula was associated with 92.7% increased odds of mortality (Table 6).

**Table 5.** Backward logistic regression analysis to evaluate the associations between mortality and different factors in emergency admitted patients with the primary diagnosis of empyema and undergoing an operation. Mortality was the dependent variable. NIS 2005-2014.

	Adult Patients with O	peration	<b>Elderly Patients with Operation</b>		
	OR (95% CI)	P	OR (95% CI)	P	
Time to Operation, Days	1.049 (1.017, 1.081)	0.002	1.037 (1.008, 1.067)	0.012	
<b>Empyema with Fistula</b>	4.081 (2.966, 5.615)	< 0.001	2.169 (1.605, 2.932)	< 0.001	
Age, Years	1.053 (1.035, 1.071)	< 0.001	1.060 (1.046, 1.074)	< 0.001	
<b>Modified Frailty Index Score</b>	1.151 (1.012, 1.309)	0.032	1.146 (1.047, 1.255)	0.003	
Sex, Female					
Invasive Diagnostic Procedure	Removed Via		Domestical Via		
Race		I	Removed Via		
Income Quartile	Backward		Backward		
Insurance	Elimination		Elimination		
Hospital Location					
	I		1		

**Table 6.** Backward logistic regression analysis to evaluate the associations between mortality and different factors in emergency admitted patients with the primary diagnosis of empyema and not undergoing an operation. Mortality was the dependent variable. NIS 2005-2014.

	Adult Patients, Not O	perated	<b>Elderly Patients, Not Operated</b>		
	OR (95% CI)	P	OR (95% CI)	P	
Age, Years	1.039 (1.005, 1.073)	0.024	1.054 (1.023, 1.086)	< 0.001	
<b>Modified Frailty Index Score</b>	1.283 (0.985, 1.672)	0.070	1.145 (0.938, 1.397)	0.180	
Empyema with Fistula			1.927 (1.133, 3.275)	0.015	
Sex, Female					
Invasive Diagnostic					
Procedure	Removed Via Backward Elimination		Removed Via  Backward		
Race					
Income Quartile					
Insurance			Elimination		
<b>Hospital Location</b>					
Hospital Length of Stay, Days					

#### **Discussion**

Time to Operation

The primary aim of this study was to evaluate associations between demographics, socioeconomic status, clinical status, comorbidities and HLOS and overall postoperative mortality in emergency admitted non-elderly adult and elderly patients with the primary diagnosis of empyema admitted emergently. Each additional day delay in time to operation increased the odds of mortality by 4.9% in adults and 3.7% in elderly patients who underwent a surgical operation. Our results are supported by Meschino et al., who showed that increasing time from admission to operation was associated with greater mortality for EGS patients. Furthermore, McIsaac et al., in a propensity score—matched observational cohort study, demonstrated a continuous, but possibly nonlinear, association of delay of urgent or emergency surgery with mortality and use of health care resources. Miraflor et al., added that delayed intubation was shown to be associated with increased mortality in trauma patients. Interestingly, emergency surgery without stabilization prior to surgical repair for total anomalous pulmonary venous connection, managed to reduce duration of mechanical ventilation without reducing survival. Understanding potential trajectories in morbidity and mortality is crucial to guiding longterm investments and policy implementation. Strategies to provide timely access to the operating

room should be considered in order to reduce mortality rate. This analysis was recorded in an exhaustive nationwide distinctive database during a 10-year period in the United States, 2005-2014. The large patient population enabled us to estimate the mortality associated with empyema, and to identify multiple adjusted predictors of in-hospital death.

#### Fistula

Our results showed that in patients with fistula, the rate of surgical procedure, invasive diagnostic procedures, mortality and HLOS are significantly higher than in those with no fistula, indicating patients in higher risk. Treatment of empyema associated with bronchopleural fistula (BPF) remains a challenge to thoracic surgeons. It is crucial to have a prompt and complete seal of BPF for a successful closure of a persistent empyema cavity. The fistula, a potentially fatal direct communication between the bronchus and pleural cavity, is associated with significant morbidity such as tension pneumothorax, aspiration, and respiratory failure and mortality. Previous studies showed that BPF-related mortality ranges from 18 to 71% in the literature. Age (>60), gender (male), and induction chemotherapy have been cited as the risk factors for postpneumonectomy BPF. Bronchopleural fistula may need prolonged HLOS for a close followup, complex surgical procedures, and management of the life-threatening conditions like sepsis, tension



pneumothorax, and respiratory failure. Systemic factors included the patient's nutritional status, diabetes mellitus, steroid use, presence of sepsis, and preoperative chemotherapy. Most fistulas with a viable bronchial stump can be managed endoscopically, using mechanical abrasion, polidocanol sclerosing agent, and cyanoacrylate glue. Pedicled muscle flap transfer combined with endoscopic therapies for bronchopleural fistula with empyema, is a feasible and efficient surgical for treatment.

#### **HLOS**

Sziklavari et al., have shown that for debilitated patients, immediate minimally invasive technique and instillation, intrathoracic vacuum therapy is a safe and viable alternative to open window thoracostomy. It has been shown to have the fastest clearance and healing rates of empyema as well as shortened HLOS. However, initial treatment with intrapleural fibrinolytic therapy or surgical procedures did not result in shorter HLOS. Bailey et al., showed that the shorter preoperative HLOS for video-assisted thoracoscopic surgery can be achieved by earlier intervention using less invasive surgical procedures. Li et al., added that primary decortication within the first 2 days of hospitalization, may also contribute to a decrease in-hospital length of stay.

#### **Conclusions**

Age and modified frailty index were the common risk factors of mortality in all patients with the primary diagnosis of empyema, regardless of surgical status. Furthermore, delay in operation and the presence of a fistula were significantly associated with in-hospital mortality in adult and elderly patients that underwent emergency surgery. In those elderly patients that did not undergo an emergency surgery and were diagnosed with an empyema, having an associated fistula was correlated with higher mortality.

#### Acknowledgement

The authors would like to thank Jonathan Butler for his help in statistical analysis.

#### **Conflict of Interest Disclosure Statement**

The authors have no conflict of interest to declare.

#### REFERENCES

- 1. Huang HC, Chang HY, Chen CW, Lee CH, Hsiue TR. Predicting factors for outcome of tube thoracostomy in complicated parapneumonic effusion for empyema. Chest. 1999;115(3):751-756. doi:10.1378/chest.115.3.751
- 2. Garvia V, Paul M. Empyema. In: StatPearls. Stat-

- Pearls Publishing; 2021. Accessed April 4, 2021. http://www.ncbi.nlm.nih.gov/books/NBK459237/
- 3. Bostock IC, Sheikh F, Millington TM, Finley DJ, Phillips JD. Contemporary outcomes of surgical management of complex thoracic infections. J Thorac Dis. 2018;10(9):5421-5427. doi:10.21037/jtd.2018.08.43
- 4. Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax. 2009;64(7):592-597.
- doi:10.1136/thx.2008.105080
- 5. Eren S, Esme H, Sehitogullari A, Durkan A. The risk factors and management of posttraumatic empyema in trauma patients. Injury. 2008;39(1):44-49. doi:10.1016/j.injury.2007.06.001
- 6. Meschino MT, Giles AE, Rice TJ, et al. Operative timing is associated with increased morbidity and mortality in patients undergoing emergency general surgery: a multisite study of emergency general services in a single academic network. Can J Surg. 2020;63(4):E321-E328. doi:10.1503/cjs.012919
- 7. McIsaac DI, Abdulla K, Yang H, et al. Association of delay of urgent or emergency surgery with mortality and use of health care resources: a propensity score-matched observational cohort study. CMAJ. 2017;189(27):E905-E912. doi:10.1503/cmaj.160576
- 8. Miraflor E, Chuang K, Miranda MA, et al. Timing is everything: delayed intubation is associated with increased mortality in initially stable trauma patients. J Surg Res. 2011;170(2):286-290.
- doi:10.1016/j.jss.2011.03.044
- 9. Xi L, Wu C, Pan Z, Xiang M. Emergency surgery without stabilization prior to surgical repair for total anomalous pulmonary venous connection reduces duration of mechanical ventilation without reducing survival. J Cardiothorac Surg. 2021;16(1):213. doi:10.1186/s13019-021-01559-y
- 10. Puskas JD, Mathisen DJ, Grillo HC, Wain JC, Wright CD, Moncure AC. Treatment strategies for bronchopleural fistula. J Thorac Cardiovasc Surg. 1995;109(5):989-995; discussion 995-996. doi:10.1016/S0022-5223(95)70325-X
- 11. Deschamps C, Bernard A, Nichols FC, et al. Empyema and bronchopleural fistula after pneumonectomy: factors affecting incidence. Ann Thorac

Surg. 2001;72(1):243-247; discussion 248. doi:10.1016/s0003-4975(01)02681-9

12. Pforr A, Pagès P-B, Baste J-M, et al. A Predictive Score for Bronchopleural Fistula Established Using the French Database Epithor. Ann Thorac Surg. 2016;101(1):287-293.

doi:10.1016/j.athoracsur.2015.06.026

13. Wright CD, Wain JC, Mathisen DJ, Grillo HC. Postpneumonectomy bronchopleural fistula after sutured bronchial closure: incidence, risk factors, and management. J Thorac Cardiovasc Surg. 1996;112(5):1367-1371. doi:10.1016/S0022-5223(96)70153-8

14. Batıhan G, Ceylan KC. Bronchopleural Fistula: Causes, Diagnoses and Management. Diseases of *Pleura*. Published online August 6, 2019. doi:10.5772/intechopen.88127

15. Laperuta P, Napolitano F, Vatrella A, Di Crescenzo RM, Cortese A, Di Crescenzo V. Postpneumonectomy broncho-pleural fistula successfully closed by open-window thoracostomy associated with V.A.C. therapy. *Int J Surg*. 2014;12 Suppl 2:S17-S19. doi:10.1016/j.ijsu.2014.08.390

16. Cardillo G, Carbone L, Carleo F, et al. The Rationale for Treatment of Postresectional Bronchopleural Fistula: Analysis of 52 Patients. Ann Thorac Surg. 2015;100(1):251-257.

doi:10.1016/j.athoracsur.2015.03.014

17. He X, He Z, Shen L, Chen G, He X. Free musculocutaneous flap transfer for refractory chronic empyema with chest wall sinus in a 43-year-old male with hemophilia A. J Thorac Dis. 2018;10(6):E416-E419. doi:10.21037/jtd.2018.05.201

18. Sziklavari Z, Ried M, Zeman F, et al. Short-term and long-term outcomes of intrathoracic vacuum therapy of empyema in debilitated patients. J Cardiothorac Surg. 2016;11(1):148.

doi:10.1186/s13019-016-0543-7

19. Segerer FJ, Seeger K, Maier A, et al. Therapy of 645 children with parapneumonic effusion and empyema-A German nationwide surveillance study. Pediatr Pulmonol. 2017;52(4):540-547. doi:10.1002/ppul.23562

20. Bailey KA, Bass J, Rubin S, Barrowman N. Empyema management: twelve years' experience since the introduction of video-assisted thoracoscopic

surgery. J Laparoendosc Adv Surg Tech A. 2005;15(3):338-341. doi:10.1089/lap.2005.15.338 21. Li S-TT, Gates RL. Primary operative management for pediatric empyema: decreases in hospital length of stay and charges in a national sample. Arch Pediatr Adolesc Med. 2008;162(1):44-48. doi:10.1001/archpediatrics.2007.10